Cartesian Therapeutics (NASDAQ:RNAC) & AngioSoma (OTCMKTS:SOAN) Head to Head Review

AngioSoma (OTCMKTS:SOAN) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, profitability, risk and earnings.

Profitability

This table compares AngioSoma and Cartesian Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AngioSoma	N/A	N/A	-1,245.34%
Cartesian Therapeutics	-510.72%	N/A	-6.03%

Volatility and Risk

AngioSoma has a beta of -0.46, indicating that its share price is 146% less volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.

Valuation and Earnings

This table compares AngioSoma and Cartesian Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AngioSoma	N/A	N/A	-$540,000.00	N/A	N/A
Cartesian Therapeutics	$34.17 million	6.96	-$219.71 million	($52.83)	-0.17

AngioSoma has higher earnings, but lower revenue than Cartesian Therapeutics.

Insider & Institutional Ownership

0.0% of AngioSoma shares are held by institutional investors. Comparatively, 86.9% of Cartesian Therapeutics shares are held by institutional investors. 57.9% of Cartesian Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations for AngioSoma and Cartesian Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AngioSoma	0	0	0	0	0.00
Cartesian Therapeutics	0	2	5	0	2.71

Cartesian Therapeutics has a consensus price target of $43.00, indicating a potential upside of 369.43%. Given Cartesian Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Cartesian Therapeutics is more favorable than AngioSoma.

Summary

Cartesian Therapeutics beats AngioSoma on 8 of the 10 factors compared between the two stocks.

About AngioSoma

AngioSoma, Inc., a wellness company, engages in the development and commercialization of dietary supplements to the medical, wellness, and adult-use markets. The company was founded in 2016 and is based in Houston, Texas.

About Cartesian Therapeutics

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.